MAPT and tauopathy: Recent studies have shown that complete loss of TMEM106B exacerbates tau pathology and tau-mediated neurodegeneration in the PS19 tauopathy mouse model [152, 198], while the T185S protective variant protected against cognitive deficits and neurodegeneration without affecting tau pathology [152] (Table 2).